Granules added that manufacturing and distribution of its existing products at the facility will continue unaffected.

The USFDA issued a warning letter to Granules India Ltd's Gagillapur facility after an August 2024 inspection highlighted ...

Granules India's shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing ...

"On February 26, 2025, the US FDA issued a Warning Letter to Granules' Gagillapur facility based on its inspection conducted ...

The Warning Letter is dated February 26, 2025 and the facility continues to hold an "Official Action Indicated" (OAI) status.

The development may temporarily delay the approval of pending product submissions from the site, but existing manufacturing ...

Granules India's Gagillapur facility receives FDA warning letter, impacting product submissions review until resolved, company remains confident in resolution.

From turning away inspectors to falsifying data and leaving "bare footprints" in production containers, two of the latest ...

Drug firm Granules India Ltd on Thursday (February 27) announced that the US FDA has issued a Warning Letter for its ...

The USFDA has issued a warning letter to Jagsonpal Pharmaceuticals for significant manufacturing lapses at its ...

James Jones resigned as FDA deputy commissioner and said the Trump administration's "indiscriminate" job cuts show "disdain for the very people necessary to implement your agenda." ...